Application of fagopyrum dibotrys freeze-dried powder in preparation of medicine for preventing or treating antimony pneumoconiosis
The freeze-dried buckwheat powder preparation process has solved the technical problem of lacking an effective treatment for antimony pneumoconiosis. The freeze-dried buckwheat powder has shown a significant inhibitory effect on pulmonary fibrosis in the prevention and treatment of antimony pneumoconiosis, providing a new drug intervention and prevention approach for occupational antimony pneumoconiosis.
Patent Information
- Application Number
- CN202610378668.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-26
- Publication Date
- 2026-05-12
AI Technical Summary
There is a lack of effective drug interventions in the current technology to treat or prevent antimony pneumoconiosis, especially for occupational pulmonary fibrosis caused by metallic antimony dust. The application of the traditional Chinese medicine buckwheat lacks theoretical basis and experimental evidence.
The freeze-dried powder of buckwheat was used as a drug. It was prepared into freeze-dried powder through water extraction, concentration and freeze drying. It was used to alleviate pulmonary fibrosis caused by antimony exposure, reduce collagen deposition and Col-1, α-SMA protein and gene expression in lung tissue, and reduce hydroxyproline content. The preparation process is mature and the quality is controllable.
The freeze-dried powder of buckwheat significantly reduces the pathological damage to lung tissue in antimony pneumoconiosis, inhibits excessive collagen expression, and improves inflammatory cell infiltration and fibrosis, providing a new drug intervention strategy for the prevention and treatment of antimony pneumoconiosis and showing good industrialization potential.